News
NRXP
1.870
-3.11%
-0.060
Weekly Report: what happened at NRXP last week (0414-0418)?
Weekly Report · 4d ago
NRX PHARMACEUTICALS INC - INCREASES MAXIMUM AGGREGATE OFFERING PRICE UNDER AUG 14 2023 ATM AGREEMENT TO $20 MILLION - SEC FILING
Reuters · 04/17 21:29
Weekly Report: what happened at NRXP last week (0407-0411)?
Weekly Report · 04/14 10:17
Weekly Report: what happened at NRXP last week (0331-0404)?
Weekly Report · 04/07 10:16
Psychedelic: Enveric, Filament Health report earnings results
TipRanks · 04/03 15:40
NRX: TERM SHEET CONTEMPLATES INVESTMENT OF $2.5 MLN TO BUY SERIES A CONVERTIBLE PREFERRED STOCK AT $50 MLN PRE-MONEY VALUATION
Reuters · 04/03 12:03
Press Release: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
Dow Jones · 04/03 12:03
Innovative Approaches and FDA Approvals Drive Buy Rating for NRX Pharmaceuticals
TipRanks · 04/02 15:55
NRX Pharmaceuticals Price Target Announced at $18.00/Share by BTIG
Dow Jones · 04/02 13:53
BTIG Initiates Coverage On NRX Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga · 04/02 13:43
NRx Pharmaceuticals initiated with a Buy at BTIG
TipRanks · 04/02 10:20
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Dow Jones · 03/31 13:24
NRX Pharmaceuticals Price Target Maintained With a $31.00/Share by D. Boral Capital
Dow Jones · 03/31 13:24
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
Benzinga · 03/31 13:14
NRx Pharmaceuticals’ Hope Therapeutics to acquire Dura Medical, no terms
TipRanks · 03/31 12:11
Weekly Report: what happened at NRXP last week (0324-0328)?
Weekly Report · 03/31 10:23
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Dow Jones · 03/24 14:44
NRX Pharmaceuticals Price Target Maintained With a $31.00/Share by D. Boral Capital
Dow Jones · 03/24 14:44
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
Benzinga · 03/24 14:34
NRx Pharmaceuticals, HOPE Therapeutics sign binding LOI with Neurospa
TipRanks · 03/24 12:20
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic.